IDSA 2016 — Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
IDSA, 2016
Voriconazole or isavuconazole is recommended as primary therapy for invasive pulmonary aspergillosis in immunocompromised patients (Strong recommendation, High-quality evidence). Serum and BAL galactomannan testing is recommended to establish microbiological diagnosis.
Clinical Context & Relevant Topics (3)
Disease ReferenceHost immune defects, neutropenic sepsis, acute respiratory failure (PJP/Aspergillus), tumor lysis syndrome, leukostasis, CAR-T CRS/ICANS, and ICU triage.
Nosocomial pneumonia developing ≥ 48 hours after admission in non-ventilated patients, host and antibiogram MDR risk tailoring, nasal MRSA PCR screening, and 7-day de-escalation.
Acute, diffuse inflammatory lung injury causing hypoxemia and bilateral infiltrates not fully explained by cardiac failure or fluid overload.